{"id":"bismuth-tetracycline-metronidazole-omeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Metallic taste (from metronidazole)"},{"rate":null,"effect":"Photosensitivity (from tetracycline)"},{"rate":null,"effect":"Black stool (from bismuth)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bismuth acts as a bactericidal agent and mucosal protectant, tetracycline and metronidazole are broad-spectrum antibiotics effective against H. pylori, and omeprazole is a proton pump inhibitor that reduces gastric acid to create an environment favorable for antibiotic activity. This combination approach targets the bacterium through multiple pathways while protecting the gastric mucosa, significantly improving eradication rates compared to dual or triple therapies.","oneSentence":"This is a quadruple therapy combining bismuth subsalicylate, tetracycline, metronidazole, and omeprazole to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppression mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:09.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT07312721","phase":"PHASE4","title":"Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis","status":"COMPLETED","sponsor":"Azfar Farogh","startDate":"2024-01-05","conditions":"Helicobacter Pylori Infection, Chronic Gastritis, Peptic Ulcer Disease","enrollment":752},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT07144657","phase":"PHASE2","title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":"MALT Lymphoma of Stomach","enrollment":40},{"nctId":"NCT05874570","phase":"PHASE4","title":"Doxycycline for Helicobacter Pylori Rescue Treatment","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-06-20","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT04531059","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Eradication Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-10-15","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT03779087","phase":"NA","title":"Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection","status":"COMPLETED","sponsor":"Ping-I (William) Hsu, M.D.","startDate":"2018-07-11","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT05850117","phase":"NA","title":"Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2020-02-10","conditions":"Helicobacter Pylori Eradication","enrollment":240},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT04879992","phase":"NA","title":"Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-05-07","conditions":"Helicobacter Pylori Infection","enrollment":413},{"nctId":"NCT05250050","phase":"PHASE4","title":"Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-25","conditions":"Helicobacter Pylori Infection","enrollment":388},{"nctId":"NCT03708848","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-12-05","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT00002682","phase":"PHASE2","title":"Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1995-08-10","conditions":"Lymphoma","enrollment":5},{"nctId":"NCT02894268","phase":"PHASE4","title":"Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2016-02","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT03555526","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-12-15","conditions":"H Pylori Infection","enrollment":320},{"nctId":"NCT03208426","phase":"PHASE4","title":"Sequential Versus Quadruple Therapy in the Second-line Treatment","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-10-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT03146325","phase":"PHASE4","title":"Helicobacter Pylori and Body Iron in Adults","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-11","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT00669955","phase":"PHASE3","title":"Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06","conditions":"Helicobacter Infections","enrollment":440},{"nctId":"NCT00712413","phase":"PHASE3","title":"Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori","status":"WITHDRAWN","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT01643785","phase":"NA","title":"Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection","status":"TERMINATED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2012-06","conditions":"Helicobacter Pylori Infection","enrollment":30},{"nctId":"NCT01938534","phase":"PHASE4","title":"Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2013-09","conditions":"Helicobacter Eradication","enrollment":440},{"nctId":"NCT01792700","phase":"PHASE4","title":"Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2003-01","conditions":"Helicobacter Infections","enrollment":648},{"nctId":"NCT01760824","phase":"NA","title":"Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2011-05","conditions":"Helicobacter Pylori Infection","enrollment":391},{"nctId":"NCT00003151","phase":"PHASE2","title":"Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-09","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT01335334","phase":"PHASE4","title":"H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study","status":"UNKNOWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-03","conditions":"H. Pylori Infection","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":199,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PYLERA","OTC OMEPRAZOLE"],"phase":"marketed","status":"active","brandName":"BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE","genericName":"BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a quadruple therapy combining bismuth subsalicylate, tetracycline, metronidazole, and omeprazole to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppression mechanisms. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}